Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
- PMID: 36600518
- PMCID: PMC9980696
- DOI: 10.1080/21645515.2022.2164140
Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
Abstract
Coxsackievirus A6 (CA6) is one of the major causative agents of herpangina and hand-foot-mouth disease (HFMD). Since 2008, CA6 has circulated widely around the world. Especially in Asia-Pacific region CA6 had even replaced enterovirus A71 (EV71) and coxsackievirus A16 (CA16) as the main prevalent strain of HFMD. In the recent 10 years, monovalent and multivalent vaccines against CA6 have been researched and developed by manufacturers from China, Korea, and the USA. The neutralizing antibody titer is a key indicator for accurately evaluating immunogenicity of vaccine. However, so far, the World Health Organization international standard for CA6 neutralizing antibody has not been available. In order to meet the needs of evaluating the immunogenicity of vaccines against CA6, the first Chinese national standard for CA6 neutralizing antibody was established, which was conducted to ensure that methods used to measure the neutralizing antibody titers against CA6 are accurate, reliable, and comparable. Three lyophilized candidate standards (29#, 39# and 44#) were produced with 0.40 ml/vial from plasma samples donated by healthy individuals. The collaborative study showed that the 29# candidate standard could effectively minimize the variability in neutralization titers between labs and across challenging viruses of different genotypes (A, D1, and D3). Therefore, the 29# candidate sample was established as the first Chinese national standard for CA6 neutralizing antibody test. This standard has good long-term stability and was assigned a potency of 150 units per milliliter (U/ml) of CA6 neutralizing antibody. It will contribute to ensure uniformity of potency or activity of vaccines and potentially therapeutic antibody preparations.
Keywords: Coxsackievirus A6; collaborative study; hand-foot-mouth disease; national standard; neutralizing antibody; potency.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures
Similar articles
-
The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.Vaccine. 2018 Jun 7;36(24):3445-3452. doi: 10.1016/j.vaccine.2018.05.005. Epub 2018 May 5. Vaccine. 2018. PMID: 29739716
-
A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.Vaccine. 2014 May 1;32(21):2406-12. doi: 10.1016/j.vaccine.2014.03.012. Epub 2014 Mar 18. Vaccine. 2014. PMID: 24657161
-
Establishment of the 1st WHO International Standard for anti-EV71 serum (Human).Biologicals. 2018 May;53:39-50. doi: 10.1016/j.biologicals.2018.03.001. Epub 2018 Mar 20. Biologicals. 2018. PMID: 29572108
-
Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide.Expert Rev Anti Infect Ther. 2015;13(9):1061-71. doi: 10.1586/14787210.2015.1058156. Epub 2015 Jun 25. Expert Rev Anti Infect Ther. 2015. PMID: 26112307 Review.
-
Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.Expert Rev Vaccines. 2018 Sep;17(9):819-831. doi: 10.1080/14760584.2018.1510326. Epub 2018 Aug 22. Expert Rev Vaccines. 2018. PMID: 30095317 Review.
References
-
- Hubiche T, Schuffenecker I, Boralevi F, Léauté-Labèoze C, Bornebusch L, Chiaverini C, Phan A, Maruani A, Miquel J, Lafon M-E, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J. 2014;33(4):e92–8. doi:10.1097/INF.0000000000000120. - DOI - PubMed
-
- Logotheti M, Pogka V, Horefti E, Papadakos K, Giannaki M, Pangalis A, Sgouras D, Mentis A.. Laboratory investigation and phylogenetic analysis of enteroviruses involved in an aseptic meningitis outbreak in Greece during the summer of 2007. J Clin Virol. 2009;46(3):270–74. doi:10.1016/j.jcv.2009.07.019. - DOI - PubMed
-
- National Health Commission of the People’s Republic of China . Diagnosis and treatment guideline on hand, foot and mouth disease (2018). Chin J Viral Dis. 2018;8(5):347–52. doi:10.3760/cma.j.issn.1674-2397.2018.03.001. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources